Eyenovia
  • Home
  • About
    • Vision
    • Leadership
  • Technology
  • Pipeline
    • MydCombi (Mydriasis)
    • MicroLine (Presbyopia)
    • MicroPine (Myopia)
  • Partners
  • Investors
  • News
  • Menu Menu

Recent Posts

  • Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase February 13, 2021
  • Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia January 25, 2021
  • Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis January 25, 2021
  • Eyenovia To Report Third Quarter 2020 Results December 16, 2020

Pipeline and Technology

  • MydCombi (Mydriasis)
  • MicroLine (Presbyopia)
  • MicroPine (Myopia)
  • Technology

Corporate Address

Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com

Copyright © 2021 Eyenovia, Inc. All rights reserved.
  • Twitter
  • Facebook
  • LinkedIn
  • Contact
  • Safe Harbor
  • Privacy Policy
  • Terms of Use
Scroll to top